Kron00,
all scientists at IMU want to get the drugs to be developed and brought to the patients. Therefore they aim for licencing / partnering deals after ph2 for all vaxx / OVs. But anything is possible and our Chair Paul Hopper is a business man too and has shown a few times that he is not opposed to sell a business.
IMO, 75% chance of partnering deals with upfront payments and income payments at later stage and 25% t/o likelihood.
As always, time will tell.
GLTA
Imugene - Charts & Price Action (New thread), page-474
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
-0.003(6.82%) |
Mkt cap ! $304.9M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.4¢ | 4.1¢ | $1.607M | 38.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 4542680 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.3¢ | 1675759 | 9 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |